Search the Newsreel

California State Teachers Retirement System Raises Position in NeoGenomics, Inc. $NEO

The California State Teachers Retirement System significantly increased its stake in NeoGenomics, Inc. (NASDAQ:NEO) by 56.8% in the first quarter, now owning 194,103 shares valued at $1.44 million. This move is reflective of a broader positive sentiment from institutional investors, who collectively own 98.5% …

Analysts Offer Insights on Healthcare Companies: BioNano Genomics (BNGO), Liquidia Technologies (LQDA) and PolyPid (PYPD)

This article provides an overview of analyst ratings for three healthcare companies: BioNano Genomics (BNGO), Liquidia Technologies (LQDA), and PolyPid (PYPD). BioNano Genomics received a "Buy" rating with a $4.00 price target, while Liquidia Technologies was given a "Hold" rating and a $90.00 price …

10x Genomics Director John R. Stuelpnagel Sells 20,000 Shares in August 2026 SEC Filing

John R. Stuelpnagel, a Director at 10x Genomics, Inc. (NASDAQ:TXG), sold a total of 20,000 shares of Class A Common Stock on August 11, 2026. The sales were conducted in two open-market transactions, with 17,000 shares sold at a weighted average price of $57.5812 …

Why 10x Genomics (TXG) Is Up 21.7% After Raising 2026 Outlook Despite Q2 Revenue Drop

Metagenomi Therapeutics, Inc. (NASDAQ:MGX) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Metagenomi Therapeutics (NASDAQ:MGX) analysts have significantly cut their revenue estimates and increased loss per share forecasts for 2026 following the company's recent quarterly results, which fell short of expectations. The consensus price target has dropped by 13% to US$7.00, reflecting decreased confidence in the …

5 Revealing Analyst Questions From 10x Genomics’s Q2 Earnings Call

Oryzon Genomics, cotización y precio de la acción hoy [ORY]

NeoGenomics Senior VP & Chief Accounting Officer Gregory Aunan Sells 80% Of Holding

NeoGenomics' Senior VP & Chief Accounting Officer, Gregory Aunan, recently sold US$321k worth of shares, representing an 80% reduction in his holdings at an average price of US$16.07. This significant insider selling event, occurring slightly below the current share price of US$16.53, raises caution …

Maxim Group Maintains Bionano Genomics(BNGO.US) With Buy Rating, Maintains Target Price $4

Maxim Group has reiterated its Buy rating for Bionano Genomics (BNGO.US), along with a maintained target price of $4. This indicates a continued positive outlook from the firm regarding the company's stock performance and valuation.

These Analysts Think Metagenomi Therapeutics, Inc.'s (NASDAQ:MGX) Sales Are Under Threat

Analysts have significantly cut their revenue and increased their loss per share estimates for Metagenomi Therapeutics, Inc. (NASDAQ:MGX) for 2026. The new consensus predicts a substantial 43% decline in revenue and increased losses per share compared to previous forecasts. This revision suggests a more …

US$49.54 - That's What Analysts Think 10x Genomics, Inc. (NASDAQ:TXG) Is Worth After These Results

Renaissance Technologies LLC Acquires New Shares in NeoGenomics, Inc. $NEO

Renaissance Technologies LLC has acquired 254,172 shares of NeoGenomics, Inc. (NASDAQ:NEO) worth approximately $1.89 million, increasing institutional ownership of the company to 98.5%. This comes as NeoGenomics exceeded Q1 earnings expectations with $0.05 EPS and $201.66 million in revenue, an 11.2% year-over-year increase. Analysts …

Technical Reactions to NEO Trends in Macro Strategies

This article provides a technical analysis of Neogenomics Inc. (NYSE: NEO) based on AI models, indicating strong sentiment across all time horizons and compelling upside potential. It outlines three distinct trading strategies (Position, Momentum Breakout, and Risk Hedging) with specific entry, target, and stop-loss …

Bionano Genomics, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:BNGO)

Bionano Genomics, Inc. published its 2026 Q2 earnings call presentation. The slide deck was released in conjunction with the company's Q2 earnings call. This article was written by SA Transcripts, which publishes thousands of quarterly earnings call transcripts.

Form 8K NeoGenomics Inc For: 11 August By Investing.com

This article reports on NeoGenomics Inc.'s Form 8K filing for August 11th. The brief notice confirms the filing, and the article is primarily a placeholder for this regulatory update. No specific details about the content of the 8K filing are provided within this particular …

NeoGenomics announces planned departure of General Counsel Alicia Olivo

NeoGenomics, Inc. announced that Alicia Olivo, Executive Vice President, General Counsel, and Business Development, will depart from her role as General Counsel effective September 21, 2026, and will assist with the transition until October 2, 2026. This news follows the company's strong second-quarter 2026 …

Metagenomi Records Wider Q2 Loss As MGX-001 Advanced Toward IND Submission

(RTTNews) - Metagenomi Therapeutics Inc. (MGX), an in vivo genome editing company, on Monday reported second quarter financial results, noting a higher loss owing to increased losses from operations and collaborations. The company specializes in in metagenomics - the study of genetic material from …

Wells Fargo cuts Metagenomi stock price target on higher R&D costs

Wells Fargo has lowered its price target for Metagenomi Inc (NASDAQ:MGX) shares to $7.00 from $9.00, while maintaining an Overweight rating, citing higher-than-expected research and development expenses and a larger net loss per share in Q2 2026. Despite the stock trading down 24% year-to-date, …

10x Genomics (TXG): Doubled, Then Doubled Again

10x Genomics (TXG) has been a significant winner for Hedgeye, with its stock price soaring over 157% since May 19 due to strong Signal Strength, favorable macroeconomic "Quads," and robust fundamental performance. The company recently reported strong second-quarter results, raised full-year guidance, and despite …

Bionano Genomics Inc (BNGO) (Q2 2026) Earnings Call Highlights: Record Flow Cell Sales and ...

Bionano Genomics Inc (BNGO) reported Q2 2026 revenue of $8.2 million, a 21% year-over-year increase, exceeding guidance, driven by record flow cell sales. Despite strong demand and increased gross margins, the company faces supply constraints for flow cells and a decline in software revenue. …

Bionano Genomics, Inc. Q2 2026 Earnings Call Summary

Bionano Genomics, Inc. Q2 2026 Earnings Call Summary - Moby Strategic Execution and Performance Drivers Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap …

Bionano Genomics earnings beat by $0.13, revenue topped estimates

Metagenomi Therapeutics reports $27.5M loss in Q2 2026

Metagenomi Therapeutics (NASDAQ: MGX) reported a significant net loss of $27.482 million in Q2 2026, widening from the previous year, and missed analyst EPS estimates. The company's collaboration revenue dropped sharply to $(0.257) million from $8.513 million in Q2 2025. Despite these financial setbacks, …

Bionano outlines $31M-$33M 2026 revenue forecast amid flow cell supply constraints

Earnings Call Insights: Bionano Genomics (BNGO) Q2 2026 MANAGEMENT VIEW * "Bionano had a strong second quarter, and that strength can be directly attributed to increased adoption by our customers," said (Chairman, Interim CEO, Interim President & Interim Principal Financial Officer Albert Luderer), adding …

Is Bionano Genomics Inc (BNGO) Undervalued After Q2 Earnings? EPS: -$7.4M, Revenue: $8.2M, GF Score: 64/100

Earnings call transcript: Bionano Genomics tops Q2 revenue view, shares edge up

Metagenomi Therapeutics: Q2 Earnings Snapshot

Form 8K Metagenomi Inc For: 10 August By Investing.com

This article from Investing.com reports that Metagenomi Inc. filed a Form 8K on August 10th. The brief piece includes a stock symbol (MGX) and indicates the stock was trading at 0.00%. The content mainly consists of standard financial market data, including various indices, commodities, …

Metagenomi Therapeutics (MGX) revenue drops as losses widen but cash tops $120M

Bionano Genomics (NASDAQ: BNGO) grows revenue amid going concern warning

Bionano Genomics presenta sus previsiones de ingresos para el tercer trimestre y el ejercicio 2026

Bionano Genomics, Inc. Q2 2026: Revenue $8.17M, EPS $(0.64) — 10-Q Summary

Bionano Genomics, Inc. reported its Q2 2026 financial results, showing a 21% increase in revenue to $8.17M, up from $6.73M in Q2 2025. Despite this growth, the company recorded a net loss of $7.42M, though the diluted EPS improved significantly from $(1.99) to $(0.64) …

Bionano Reports Second Quarter 2026 Results and Provides a Business Update

Bionano has reported its second-quarter 2026 financial results, which include updates on its operational performance and strategic initiatives. The company also provided a comprehensive business update detailing its progress and future outlook.